Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 18 of 99 for:    Oleic Acids

Effect of Dietary Fatty Acids on Cardiovascular Disease Risk Indicators and Inflammation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02145936
Recruitment Status : Completed
First Posted : May 23, 2014
Last Update Posted : July 13, 2018
Sponsor:
Information provided by (Responsible Party):
Tufts University

Brief Summary:
The purpose of this study is to to determine the effect of habituation to diets with different types of dietary fat (stearic, palmitic and oleic) on selected Cardiovascular Disease (CVD) risk indicators with an emphasis on inflammation.

Condition or disease Intervention/treatment Phase
Dyslipidemia Other: diet Not Applicable

Detailed Description:
Vegetable oils high in the specific fatty acids of interest - stearic (found in cocoa butter, meats), palmitic (found in meats, dairy and some plant oils) and stearic acid's metabolic product, oleic (found in olive and corn oil) - will be used to displace each other in a standardized diet and fed to mildly hypercholesterolemic postmenopausal women using a randomized-controlled crossover design. A critical issue remains unresolved - the relative comparability among . The findings from this research study will enable us to understand the mechanism and potential health effect of different types of fats. Each of the diet phases will be 5 weeks in length with a 2-4 week break between phases. All food and drink will be provided to study volunteers. Blood pressure and body weight will be monitored once per week and adjustments made, if necessary, to maintain a stable weight. During the 5th week of each diet phase, volunteers will come to the center on 3 consecutive days to provide fasting blood samples and a non-fasting blood sample.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Dietary Fatty Acids on Cardiovascular Disease Risk Indicators and Inflammation.
Study Start Date : January 2013
Actual Primary Completion Date : June 2017
Actual Study Completion Date : December 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: oleic acid diet
Participants are provided with meals enriched in oleic acid (18:1)
Other: diet
Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.

Experimental: palmitic acid diet
Participants are provided with meals enriched in palmitic acid (18:0)
Other: diet
Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.

Experimental: stearic acid diet
Participants are provided with meals enriched in stearic acid (18:0)
Other: diet
Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.




Primary Outcome Measures :
  1. inflammation [ Time Frame: 15-weeks ]
    interleukine (IL)-6, tumor necrosis factor (TNF)-alpha, monocyte chemoattractant protein (MCP)-1, C-reactive protein (CRP), soluble forms of intercellular adhesion protein (slCAM)-1, vascular cell adhesion protein (sVCAM)-1, sE-selectin, sP-selectin and li0poprotein associated phospholipase A2 (LpPLA2).


Secondary Outcome Measures :
  1. lymphocyte proliferation and ex vivo cytokine secretion [ Time Frame: 15 weeks ]
    IL-1, IL-6, TNF-alpha, and prostaglandin E2 (PGE2)

  2. plasma lipids and lipoproteins [ Time Frame: 15 weeks ]
    TC, HDL, LDL

  3. desaturase activity [ Time Frame: 15 weeks ]
    8CD, D6D, D5D

  4. insulin sensitivity [ Time Frame: 15 weeks ]
    glucose, insulin

  5. coagulation biomarkers [ Time Frame: 15 weeks ]
    prothrombin time (PT), partial thromboplastin time (PTT)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

The inclusion and exclusion criteria for both studies A and B are identical.

  • Postmenopausal women (menopause defined by complete natural cessation of menses for >12 months or a bilateral oophorectomy).
  • Age >50 to < 85 years
  • BMI >20 to <35 kg/m2
  • LDL-cholesterol >100 mg/dL
  • CRP <10 ug/dL
  • Normal fasting plasma glucose levels (<120 mg/dL)
  • Not taking medication known to affect lipid metabolism:

HMG-CoA reductase inhibitors (statins)

  • Bile Acid Sequestrants (Cholestyramine, Colestipol, Colesevelam, etc.)
  • Cholesterol Absorption Inhibitors (Ezetimibe [Zetia])
  • Nicotinic Acid Agents (Niacin, Niacor, Slo-Niacin, etc)
  • Fibrates (Gemfibrozil, Clofibrate, Ciprofibrate, Fenofibrate [Tricor], etc)
  • Probucol
  • Anticoagulants (Coumadin, Heparin, Plavix, etc)
  • Hormone therapy medications containing estrogen
  • Acetylsalicylic acid containing medications, aspirin
  • Diphenylhydantoin
  • Supplements containing fatty acids (Fish Oil, Flaxseed, etc.) and any other compounds that affect lipid metabolism (red yeast rice, etc.) for at least 3 months prior to participation in the study
  • Anabolic steroids
  • Hydrocortisone

    • Normal kidney function as assessed by serum creatinine and blood urea nitrogen
    • Normal liver function as assessed by serum glutamic pyruvic transaminase, serum glutamic oxaloacetic transaminase and alkaline phosphatase
    • Normal thyroid function as assessed by serum TSH
    • Normal gastrointestinal function
    • Normotensive on or off medication
    • Non-smoker for at least 2 years
    • Alcohol intake < 7 drinks per week, and willingness to abstain from consuming alcohol while participating in the study.
    • Consistent physical activity
    • Willingness to follow protocol as detailed in the Institutional Review Board (IRB) approved consent form.

Exclusion criteria:

  • Men
  • Women who have had a double mastectomy
  • Age < 50 and > 85 years
  • BMI < 20 and > 35 kg/m2
  • LDL-cholesterol <100 mg/dL
  • CRP > 10 ug/dL
  • Abnormal fasting plasma glucose levels >120 mg/dL
  • Use of medications known to affect lipid metabolism:

    • HMG-CoA reductase inhibitors (statins)
    • Bile Acid Sequestrants (Cholestyramine, Colestipol, Colesevelam, etc.)
    • Cholesterol Absorption Inhibitors (Ezetimibe [Zetia])
    • Nicotinic Acid Agents (Niacin, Niacor, Slo-Niacin, etc)
    • Fibrates (Gemfibrozil, Clofibrate, Ciprofibrate, Fenofibrate [Tricor], etc)
    • Anticoagulants (Coumadin, Heparin, Plavix, etc)
    • Hormone therapy medications containing estrogen
    • Probucol
    • Acetylsalicylic acid containing medications, aspirin
    • Diphenylhydantoin
    • Supplements containing fatty acids (Fish Oil, Flaxseed, etc.) and any other compounds that affect lipid metabolism (red yeast rice, etc.) in the last 3 months prior to participation in the study
    • Anabolic steroids and hydrocortisone
  • Renal or kidney disease, as defined by a history of chronic kidney disease or by glomerular filtration rate of < 60 ml.min/1.73 m2 calculated from screening blood tests.
  • Hypothyroidism or hyperthyroidism, as defined as screening TSH outside of normal ranges (<0.4 or >4.5), unless controlled with medication for at least 6 months
  • Gastrointestinal disease
  • Uncontrolled hypertension or high BP reading at the discretion of the study physician or nurse
  • Established cardiovascular disease as defined by history of myocardial infarction, stroke, heart failure, coronary artery bypass graft, stenosis >50%, angina and peripheral arterial disease)
  • Anemia, as defined by screening haemoglobin <11.7g/dL.
  • Liver disease, as defined by a history of chronic hepatitis B or C, cholestatic or cirrhotic liver disease, nonalcoholic fatty liver disease, elevations of SGPT or SGOT greater than 1.5 times the upper limit of normal at screening, bilirubin greater than 2 mg/dL (in the absence of benign causes of elevated bilirubin such as Gilbert's syndrome) at screening, or albumin below the lower limit of normal.
  • Type I and II diabetes
  • Any non-steroidal anti-inflammatory drugs (NSAID) or antihistamine use by subject for 72 hours prior to blood draws
  • Smoking or use of nicotine-containing products within the past 2 years
  • Alcohol intake > 7 drinks per week or unwillingness to abstain from consuming alcohol while participating in the study
  • Unwillingness to maintain body weight during participation in the study
  • Unwillingness to adhere to diet and study protocol
  • Weight gain or loss of more than 15 lb within 6 months prior to enrollment
  • Vegetarians and those with food allergies or aversions
  • Non-English speaking subjects
  • No Social Security number
  • Women who have a history of difficulty with blood draws
  • Blood donation within the past 8 weeks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02145936


Locations
Layout table for location information
United States, Massachusetts
Jean Mayer Human Nutrition Research Center on Aging
Boston, Massachusetts, United States, 02111
Sponsors and Collaborators
Tufts University
Investigators
Layout table for investigator information
Principal Investigator: Alice H Lichtenstein, D.Sc. Tufts University/HNRCA

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Tufts University
ClinicalTrials.gov Identifier: NCT02145936     History of Changes
Other Study ID Numbers: 1541 - Fatty Acid Pilot
First Posted: May 23, 2014    Key Record Dates
Last Update Posted: July 13, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Tufts University:
fatty acid

Additional relevant MeSH terms:
Layout table for MeSH terms
Inflammation
Cardiovascular Diseases
Dyslipidemias
Pathologic Processes
Lipid Metabolism Disorders
Metabolic Diseases
Palmitic Acid
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action